Human Stem Cells Institute OJSC (HSCI) is a Russian public biotech company founded in 2003.

HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy and biopharmaceutics.

The Company aims to foster a new culture of medical care – developing new health care opportunities in such areas as personalized and preventive medicine.

HSCI owns the largest family cord blood stem cell bank in Russia – Gemabank, as well as the reproductive cell and tissue bank Reprobank (personal storage and donation).

The Company launched Neovasculgen®, the first-in-class gene-therapy drug for treating Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

HSCI is implementing a socially significant project to create its own Russia-wide network of Genetico medical centers & testing lab to provide a range of genetic diagnostic and consulting services with the aim of early identification, prediction and prophylactic treatment of genetic disorders (incl. PGD and NIPT among others).

The Company actively promotes its products on the Russian market and intends to open new markets throughout the world.

HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.

Ask a question

Vitamin A: a simple way to increase the collagen level in the skin

Local application of products on the basis of retinoic acid (in the form of creams containing vitamin A in the concentration of 0.025–1% for 1 to 12 months) results in a visible improvement of skin condition.

The matter is that vitamin A promotes the increase of collagen level in the derma owing to its interaction with receptors on the surface of skin fibroblasts. Moreover, the use of products on the basis of retinoic acid leads to the decrease of metalloproteinase activity and, therefore, to the decrease of skin collagen destruction. At the same time, genes encoding procollagen types I and III are activated, which leads to the increase of the amount of newly formed collagen fibers.

As a result, after a long-term application of vitamin A-containing products, the increase of newly formed collagen level is observed in the skin as well as the destruction of "old" collaged fibers is diminished, which leads to the increase of skin density and to the correction of wrinkles. That is why creams containing vitamin A can be efficiently used to correct both chronological age-related skin changes and UV light-related skin changes.

Nevertheless, one should keep in mind that vitamin A is an active substance possessing photo-sensibilizing effect which must be applied overnight (possibly during cold seasons) and is not applicable for persons under age of 35–40 years.

  • Hyaluronic acid: for those who take risk
  • What is the SPRS therapy and how does it fight skin aging?
  • Botox. Poison and current for face skin
  • How many the SPRS procedures should one take to achieve the optimal result? How often
  • must they be repeated?
  • What is the cost of the SPRS therapy course?